Popova O D, Zubkova O V, Ozharovskaia T A, Zrelkin D I, Voronina D V, Dolzhikova I V, Shcheblyakov D V, Naroditsky B S, Logunov D Yu, Gintsburg A L
FSBI «National Research Centre for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya» of the Ministry of Health of Russia.
Vopr Virusol. 2021 May 15;66(2):91-102. doi: 10.36233/0507-4088-33.
The Lassa virus one of the main etiological agent of hemorrhagic fevers in the world: according to WHO estimates, it affects 100,000 to 300,000 people annually, which results in up to 10,000 deaths [1]. Although expansion of Lassa fever caused by this pathogen is mostly limited to the West African countries: Sierra Leone, Liberia, Guinea and Nigeria, imported cases have been historically documented in Europe, the United States of America (USA), Canada, Japan, and Israel [2]. In 2017, WHO included the Lassa virus in the list of priority pathogens in need of accelerated research, development of vaccines, therapeutic agents and diagnostic tools regarding infections they cause [3]. This review describes main technological platforms used for the development of vaccines for the prevention of Lassa fever.
据世界卫生组织估计，每年有10万至30万人感染，导致多达1万人死亡[1]。尽管这种病原体引起的拉沙热传播大多局限于西非国家：塞拉利昂、利比里亚、几内亚和尼日利亚，但历史上在欧洲、美利坚合众国（美国）、加拿大、日本和以色列都有输入病例的记录[2]。2017年，世界卫生组织将拉沙病毒列入需要加速研究、开发针对其所致感染的疫苗、治疗药物和诊断工具的优先病原体名单[3]。本综述描述了用于开发预防拉沙热疫苗的主要技术平台。
